BIOSINO BIO-TEC (08247) released their annual performance report, showing a net loss of 51.142 million yuan, an increase of 20.24% compared to the previous year.
North Control Biotechnology (08247) announced its annual performance for the year ended December 31, 2025. The group achieved an operating income of 184.3 million yuan, a decrease of 30% year-on-year; the net loss attributable to the owners of the parent company was 51.142 million yuan, an increase of 20.24% year-on-year; the loss per share was 0.353 yuan.
BIOSINO BIO-TEC (08247) announced its annual performance for the year ending December 31, 2025. The group achieved an operating income of 184.3 million RMB, a year-on-year decrease of 30%. The loss attributable to equity holders of the parent company was 51.142 million RMB, an increase of 20.24% compared to the previous year. The loss per share was 0.353 RMB.
Related Articles

Shenzhen New Land Tool Planning & Architectural Design Development (00456) announced its annual performance, with shareholders' losses amounting to 221 million Hong Kong dollars, an increase of 73.1% compared to the previous year.

GREEN INTL HLDG (02700) announced its annual performance with a net loss attributable to shareholders of HK$3.866 million, an increase of 379.06% year-on-year.

Dongfang Electric Corporation (01072) announced its performance for the year 2025, with a net profit attributable to shareholders of 3.831 billion yuan, representing a year-on-year increase of 31.11%. It plans to distribute a dividend of 5.3 yuan for every 10 shares.
Shenzhen New Land Tool Planning & Architectural Design Development (00456) announced its annual performance, with shareholders' losses amounting to 221 million Hong Kong dollars, an increase of 73.1% compared to the previous year.

GREEN INTL HLDG (02700) announced its annual performance with a net loss attributable to shareholders of HK$3.866 million, an increase of 379.06% year-on-year.

Dongfang Electric Corporation (01072) announced its performance for the year 2025, with a net profit attributable to shareholders of 3.831 billion yuan, representing a year-on-year increase of 31.11%. It plans to distribute a dividend of 5.3 yuan for every 10 shares.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


